HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) to start taking orders for its new 2,002-gene HTG EdgeSeq Autoimmune Panel

The USA based company HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) stock observed trading -80.56% off 52-week high price. On the other end, the stock has been noted 38.33% away from low price over the last 52-weeks. The stock disclosed a move of -8.48% away from 50 day moving average and -56.38% away from 200 day moving average. Moving closer, we can see that shares have been trading 7.28% off 20-day moving average.

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG) recently reported it will start taking orders for its new 2,002-gene HTG EdgeSeq Autoimmune Panel, which is predictable to be commercially accessible for purchase in kit form or as a service in HTG’s VERI/O laboratory at the end of October 2019. The HTG EdgeSeq Autoimmune Panel provides a comprehensive look into immune system dysfunction, discovery of new biomarkers and the discovery of predictive signatures of drug response in the autoimmune space. The panel is designed to address many questions about autoimmune disorders, which are chronic and often difficult to accurately diagnose. Autoimmune disorders represent a large and growing market, with yearly direct U.S. healthcare costs for the treatment of autoimmune disorders being nearly double the direct U.S. healthcare costs for the treatment of cancer, and several of the largest selling pharmaceutical products are targeted towards autoimmune diseases.

“Autoimmune disorders represent a growing market, and we have seen important interest and strong demand from our pharmaceutical consumers for comprehensive, molecular profiling tools spanning the continuum of consumers’ development programs, from bio-marker discovery to companion diagnostic development,” stated Michael Hrubiak, Vice President of Marketing at HTG. “While there are treatments for many autoimmune diseases, our goal is to provide better tools for more effective diagnosis, to enable better treatment of patients afflicted with these disorders. We believe our autoimmune panel is one more step forward towards achieving that goal, and we are excited to be part of the solution.”

HTG Molecular Diagnostics, Inc. moved with change of -2.92% to $0.83 with the total traded volume of 85054 shares in recent session versus to an average volume of 305.22K. The stock was observed in the 5 days activity at -4.64%. The one-month performance of stock was 5.92%. HTGM’s shares are at -43.15% for the quarter and driving a -76.82% return over the course of the past year and is now at -67.32% since this point in 2018.  Right now, the stock beta is 1.5. The average volatility for the week and month was at 6.28% and 11.11% respectively. There are 52.63M shares outstanding and 45.03M shares are floated in market.


Zachary Harrison

Zachary Harrison Healthcare Reporter I am an outstanding Healthcare writer, and analyst. Before I joined News Billion, I already was a well-known business analyst. I wrote an analysis of the market for famous financial outlets. My research articles were easy to understand, full of details and objective. I believe that every community, regardless of size, deserves top-notch news coverage from my online news portal. That principle guides the decisions I makes in daily news coverage. Mailing address: 936 Watkins Farm Road, Nicholson, GA 30565, USA Zip code: 30565 Phone number: 517-788-1142 Email: [email protected]

Leave a Reply

Your email address will not be published. Required fields are marked *